{"nctId":"NCT01646398","briefTitle":"A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older","startDateStruct":{"date":"2012-06"},"conditions":["Pneumococcal Vaccines","Pneumococcal Conjugate Vaccine"],"count":764,"armGroups":[{"label":">= 65-year age group-13vPnC","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent pneumococcal conjugate vaccine"]},{"label":">= 65-year age group-23vPS","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 23-valent pneumococcal polysaccharide vaccine"]}],"interventions":[{"name":"13-valent pneumococcal conjugate vaccine","otherNames":["13vPnC"]},{"name":"23-valent pneumococcal polysaccharide vaccine","otherNames":["23VPS"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.\n2. Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.\n\nExclusion Criteria:\n\n1. History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.\n2. Previous vaccination with any licensed or experimental pneumococcal vaccine.\n3. Documented Streptococcus pneumoniae infection within the past 5 years.\n4. Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes 1 Month After Vaccination","description":"Antibody-mediated serum OPA against each of the 12 pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1016","spread":null},{"groupId":"OG001","value":"392","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"347","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1995","spread":null},{"groupId":"OG001","value":"1440","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1901","spread":null},{"groupId":"OG001","value":"1361","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"858","spread":null},{"groupId":"OG001","value":"379","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1028","spread":null},{"groupId":"OG001","value":"1059","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2015","spread":null},{"groupId":"OG001","value":"938","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"985","spread":null},{"groupId":"OG001","value":"429","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"773","spread":null},{"groupId":"OG001","value":"388","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"456","spread":null},{"groupId":"OG001","value":"180","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titers for Serotype 6A 1 Month After Vaccination","description":"For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"47.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 12 Common Serotypes and Serotype 6A 1 Month After Vaccination","description":"Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolonoy OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1016","spread":null},{"groupId":"OG001","value":"392","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"347","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1995","spread":null},{"groupId":"OG001","value":"1440","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1901","spread":null},{"groupId":"OG001","value":"1361","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"858","spread":null},{"groupId":"OG001","value":"379","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1028","spread":null},{"groupId":"OG001","value":"1059","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2015","spread":null},{"groupId":"OG001","value":"938","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"985","spread":null},{"groupId":"OG001","value":"429","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"773","spread":null},{"groupId":"OG001","value":"388","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"456","spread":null},{"groupId":"OG001","value":"180","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2122","spread":null},{"groupId":"OG001","value":"676","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination","description":"Local reactions reported using an electronic diary. Redness and swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \\[cm\\]; Moderate (5.1 to 10.0 cm); Severe (\\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null},{"groupId":"OG001","value":"38.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"16.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination","description":"Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (\\>=) 37.5 degrees Celsius \\[C\\], fatigue, headache, chills, rash, vomiting, decreased appetite, new muscle pain, aggravated muscle pain, new joint pain, aggravated joint pain, use of medication to treat fever and use of medication to treat pain. All reports of fever \\>=39 degrees C in 13vPnC and 23vPS were confirmed as data entry errors.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":382},"commonTop":["Pain (Any)","Pain (Mild)","Redness (Any)","New muscle pain","Limitation of arm movement (Any)"]}}}